Tech Company Financing Transactions
Alumis Funding Round
On 1/7/2022, Alumis secured $200 million in Series B investment from Matrix Capital Management and private investors.
Transaction Overview
Company Name
Announced On
1/7/2022
Transaction Type
Venture Equity
Amount
$200,000,000
Round
Series B
Investors
Matrix Capital Management (Lead Investor)
Proceeds Purpose
Proceeds from the financing will be used to continue to advance Alumis' pipeline, led by ESK-001, a highly selective and potentially best in class TYK2 inhibitor with greater selectivity for TYK2 over JAK1 compared to current therapies in clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA 94105
USA
San Francisco, CA 94105
USA
Phone
Undisclosed
Website
Email Address
Overview
Alumis (formerly Esker Therapeutics) is a precision medicines company with the mission to transform the lives of patients with autoimmune diseases. Our experienced leadership team brings a proven track record in precision drug development of groundbreaking therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
June Lee
Chief Information Officer
David Zhang
VP - Bus. Development
Mark Bradley
Browse more venture capital transactions:
Prev: 1/7/2022: Carsome venture capital transaction
Next: 1/7/2022: Little Otter venture capital transaction
Share this article
About Database of VC Transactions
We report on tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs